Home > Compound List > Compound details
768-94-5 molecular structure
click picture or here to close

adamantan-1-amine

ChemBase ID: 791
Molecular Formular: C10H17N
Molecular Mass: 151.24868
Monoisotopic Mass: 151.13609955
SMILES and InChIs

SMILES:
NC12CC3CC(C1)CC(C2)C3
Canonical SMILES:
NC12CC3CC(C2)CC(C1)C3
InChI:
InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
InChIKey:
DKNWSYNQZKUICI-UHFFFAOYSA-N

Cite this record

CBID:791 http://www.chembase.cn/molecule-791.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
adamantan-1-amine
IUPAC Traditional name
adamantan-1-amine
amantadine
amantidine
Brand Name
Endantadine
Gen-Amantadine
Mantadine
Pk-Merz
Symadine
Symmetrel
Synonyms
Amantadine
Adamantan-1-amine
1-Adamantylamine
Adamantan-1-amine
Tricyclo[3.3.1.1~3,7~]decan-1-amine
1-Aminoadamantane
Amantadine HCL
Adamantamine
Adamantanamine
Adamantylamine
Amantadine Base
Amantidine
Aminoadamantane
1-aminoadamantane
Amantadine Hydrochloride
Amantadine
1-Adamantanamine
1-金刚烷胺
CAS Number
768-94-5
EC Number
212-201-2
MDL Number
MFCD00074732
PubChem SID
160964254
PubChem CID
2130
CHEBI ID
2618
ATC CODE
N04BB01
CHEMBL
660
Chemspider ID
2045
DrugBank ID
DB00915
KEGG ID
D07441
Unique Ingredient Identifier
BF4C9Z1J53
Wikipedia Title
Amantadine
Medline Plus
a682064

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
H Acceptors H Donor
LogD (pH = 5.5) -1.5643042  LogD (pH = 7.4) -1.3837394 
Log P 1.4659475  Molar Refractivity 45.5356 cm3
Polarizability 18.504875 Å3 Polar Surface Area 26.02 Å2
Rotatable Bonds Lipinski's Rule of Five true 
Log P 2.53  LOG S -3.25 
Solubility (Water) 8.46e-02 g/l 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
6290 mg/L (freely soluble) expand Show data source
Melting Point
206-208°C expand Show data source
ca 200°C subl. expand Show data source
Hydrophobicity(logP)
2.3 expand Show data source
Storage Warning
Harmful/Irritant expand Show data source
RTECS
YD1925000 expand Show data source
European Hazard Symbols
X expand Show data source
Risk Statements
22-36/37/38 expand Show data source
Safety Statements
26-36/37 expand Show data source
TSCA Listed
expand Show data source
GHS Pictograms
GHS06 expand Show data source
GHS Hazard statements
H301-H315-H319-H335 expand Show data source
GHS Precautionary statements
P261-P301+P310-P305+P351+P338-P302+P352-P405-P501A expand Show data source
Admin Routes
oral expand Show data source
Bioavailability
well absorbed expand Show data source
Excretion
renal expand Show data source
Half Life
10–14 hours, in renal impairment up to 7–10 days expand Show data source
Metabolism
negligible expand Show data source
Protein Bound
approx 67% expand Show data source
Legal Status
Rx-only (US) expand Show data source
Pregnancy Category
C expand Show data source
Mechanism of Action
Apparent virucidal mechanism: influenza type-A specific; influenza type-A viral nucleic-acid into host-cell expand Show data source
Dopaminergic expand Show data source
Exact virucidal mechanism not completely understood expand Show data source
May cause dopamine release from central sites other than the substantia-nigra expand Show data source
May interfere with viral penetration into cells. expand Show data source
Postulated antiparkinsonian mechanism: causes dopamine release from dopaminergic terminals that may remain in the substantia-nigra of parkinsonian patients expand Show data source
Purity
98% expand Show data source
Application(s)
Also has antiparkinsonian props. expand Show data source
Antiviral agent expand Show data source
prophylactic drug for influenza expand Show data source

DETAILS

DETAILS

DrugBank DrugBank Wikipedia Wikipedia
DrugBank - DB00915 external link
Item Information
Drug Groups approved
Description An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. [PubChem]
Indication For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Pharmacology Amantadine is an antiviral drug which also acts as an antiparkinson agent, for which it is usually combined with L-DOPA when L-DOPA responses decline (probably due to tolerance). It is a derivate of adamantane, like a similar drug rimantadine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. It has been shown to cause an increase in dopamine release in the animal brain, and does not possess anticholinergic activity.
Toxicity Deaths have been reported from overdose with amantadine. The lowest reported acute lethal dose was 2 grams. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress (including ARDS) have been reported. Renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects that have been reported include insomnia, anxiety, aggressive behavior, hypertonia, hyperkinesia, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucination, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed in cases where a drug overdose has occurred.
Affected Organisms
Humans and other mammals
Various viruses
Biotransformation No appreciable metabolism, although negligible amounts of an acetyl metabolite have been identified.
Absorption Amantadine is well absorbed orally from the gastrointestinal tract.
Half Life Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.
Protein Binding Approximately 67% bound to plasma proteins over a concentration range of 0.1 to 2.0 µg/mL.
Elimination It is primarily excreted unchanged in the urine by glomerular filtration and tubular secretion.
Distribution * 3 to 8 L/kg [healthy subjects]
Clearance * 0.2 - 0.3 L/hr/kg
* 0.10 +/- 0.04 L/hr/kg [healthy, elderly male]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • • Aldrich Library of FT-IR Spectra, 1st edn. , 1985, 1 , 321A; 321B, (ir)
  • • Aldrich Library of 13C and 1H FT NMR Spectra , 1992, 1 , 1229C, (nmr)
  • • Aldrich Library of FT-IR Spectra: Vapor Phase , 1989, 3 , 409D, (ir)
  • • Stetter, H. et al. , Angew. Chem. , 1959, 71 , 429, (synth)
  • • Stetter, H. et al. , Chem. Ber. , 1960, 93 , 226, (synth)
  • • Davies, W.L. et al. , Science (Washington, D.C.) , 1964, 144 , 862, (use)
  • • Fort, R.C. et al. , J.O.C. , 1965, 30 , 789, (pmr)
  • • Kovacic, P. et al. , Tet. Lett. , 1968, 5833, (synth)
  • • Geluk, H. et al. , J. Med. Chem. , 1969, 12 , 712, (N-cyano)
  • • Schulman, J.L. , Handb. Exp. Pharmacol. , 1982, 61 , 137, (rev, pharmacol)
  • • Kirschbaum, J. , Anal. Profiles Drug Subst. , 1983, 12 , 1, (rev, synth, anal)
  • • Beacutelanger-Garieacutepy, F. et al. , Acta Cryst. C , 1987, 43 , 756, (cryst struct)
  • • Negwer, M. , Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag , 1987, 1735
  • • Aoki, F.Y. et al. , Clin. Pharmacokinet. , 1988, 14 , 35, (rev, pharmacol)
  • • Bakke, J.M. et al. , Acta Chem. Scand. , 1989, 43 , 399, (synth)
  • • Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press , 1993, 833 Proumlhl, H.-H. et al. , Acta Cryst. C , 1997, 53 , 1434-1436, (N-Ac, synth, cryst struct)
  • • Tsutsui, H. et al. , Bull. Chem. Soc. Jpn. , 1999, 72 , 1869-1878, (synth, pmr, cmr)
  • • Lewis, R.J. , Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AED250; TJG250
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle